个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Cai Maoping[1,2,3] * ; Song Xian-Lu[4] * ; Li Xin-An[5] * ; Chen Mingkun[1,2,6] * ; Guo Jiading[1,2] ; Yang Dong-Hua[7] ; Chen Zhanghui[3] ; Zhao Shan-Chao[1,2,6,*1] ;
机构： [1]Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China [2]The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China [3]Zhanjiang Institute of Clinical Medicine, Central People’s Hospital of Zhanjiang, Zhanjiang 524045, Guangdong, PR China [4]Department of Radiotherapy, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, PR China [5]School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, PR China [6]Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, PR China [7]New York College of Traditional Chinese Medicine, Mineola 11501, NY, USA
出处：
DOI： 10.1016/j.drup.2023.100962
ISSN：

关键词： Metastatic castration-resistance prostate cancer (mCRPC) Drug resistance Chemotherapy Androgen receptor signaling inhibitors (ARSIs) Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi)

摘要：
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：
The authors gratefully acknowledge the funds from the National Natural Science Foundation of China (81972394, 82272856, 81971886 and 82170053), the Natural Science Foundation of Guangdong Province (2020A1515010066 and 2022A1515010437), the President’s Foundation of the Third Affiliated Hospital of Southern Medical University (No. YM2021010 and YM2021011) and the Zhujiang Talent Program (2019QN01Y279).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 药学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 药学
第一作者：
第一作者机构： [1]Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China [2]The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China [3]Zhanjiang Institute of Clinical Medicine, Central People’s Hospital of Zhanjiang, Zhanjiang 524045, Guangdong, PR China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China [2]The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China [6]Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, PR China [*1]Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China
推荐引用方式(GB/T 7714)：
Cai Maoping,Song Xian-Lu,Li Xin-An,et al.Current therapy and drug resistance in metastatic castration-resistant prostate cancer[J].Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.2023,68:100962.doi:10.1016/j.drup.2023.100962.
APA：
Cai Maoping,Song Xian-Lu,Li Xin-An,Chen Mingkun,Guo Jiading...&Zhao Shan-Chao.(2023).Current therapy and drug resistance in metastatic castration-resistant prostate cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,68,
MLA：
Cai Maoping,et al."Current therapy and drug resistance in metastatic castration-resistant prostate cancer".Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 68.(2023):100962

相关文献

[1]疣毒净诱导H8细胞凋亡作用机制 [2]Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. [3]Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma. [4]Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer [5]多重耐药鲍曼不动杆菌的耐药性及其耐药基因分析 [6]Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer [7]Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs [8]The Role of Exosomal microRNA in Cancer Drug Resistance. [9]Caveolin-1, a stress-related oncotarget, in drug resistance [10]院内感染病原菌变化趋势及耐药性分析

资源点击量：2022 今日访问量：0 总访问量：648 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号